KEYNOTE-A39 trial
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
Anika Sharma
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
